Stock Ticker

  • Loading stock data...

Myriad Genetics (NASDAQ:MYGN) Shares Stop Bleeding on Positive Study of Prenatal Genetics Test

It’s certainly been a white-knuckle ride in 2019 for shareholders of the molecular diagnostics and precision medicines company Myriad Genetics (NASDAQ: MYGN), with shares doubling and getting halved over a few weeks this summer. A slow climb starting in June from $22 culminated with a 55% explosion on August 1-2 to $48 thanks to news […]

Sign Up To Get Our Latest Stocks Alerts